While activation of TAK1 is reported to exacerbate brain damage, pharmacological inhibition of TAK1 using 5Z-7-Oxozeaenol exerts neuroprotection after subarachnoid hemorrhage as well as cerebral ischemia [23, 25, 26]. The gene discussed is MAP3K7; the disease is Cerebral ischemia.